Dapagliflozin vs empagliflozin in patients with chronic heart failure: a registry analysis.

ABSTRACT:

Aim

To assess the relative efficacy of dapagliflozin and empagliflozin in routinely treated chronic heart failure (CHF) patients.

Methods

Data from a registry of prevalent and incident CHF patients were used to set up cohorts (new-user design) of patients started on dapagliflozin or empagliflozin in addition to other guideline-directed therapy. Cohorts were mutually balanced on a range of characteristics, and were assessed for the incidence of a composite of all-cause death/major adverse cardiac events (primary outcome) over the initial 6 months of treatment, and for New York Heart Association (NYHA) functional class at 6 months (secondary outcome). Frequentist and Bayes estimates were generated for the dapagliflozin vs empagliflozin comparison.

Results

In both preval

SUBMITTER: Jurin I 

PROVIDER: S-EPMC12093124 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature